Which is better, ONC or RPRX?

On the Buffett-Fit framework, BeOne Medicines Ltd. (ONC) currently grades higher than RPRX — 62/100 (D grade) vs 66/100 (C). That said, "better" depends on which framework you trust — ONC wins on Philip Fisher, Peter Lynch, Joel Greenblatt, and Terry Smith; RPRX wins on Warren Buffett, Benjamin Graham, and Charlie Munger. The full pillar breakdown is on this page.

Should I buy ONC or RPRX?

This page is an educational comparison, not investment advice. Both ONC and RPRX are graded against the same Buffett 5-pillar framework (moat, earnings durability, management quality, financial health, valuation) plus six other documented investor frameworks. Read the side-by-side breakdown to see which one matches the criteria you care about most — and always do your own research before making any investment decision.

Is ONC better than RPRX for value investing?

The two are close on the headline Buffett-Fit score (62/100 vs 66/100), so "better for value investing" depends on which pillar you weight most. The five Buffett pillars + six other frameworks are broken down side-by-side on this page so you can pick the one that fits your style.

What's the difference between ONC and RPRX on Warren Buffett's framework?

Both stocks are evaluated on the same five pillars: economic moat (durable competitive advantage), earnings durability (consistent profitability), management quality (capital allocation), financial health (conservative balance sheet), and valuation (margin of safety). ONC currently scores 62/100 (D grade); RPRX scores 66/100 (C grade). The "Where each wins" section on this page breaks down which pillar each stock dominates.

Which has the stronger moat, ONC or RPRX?

Moat strength is one of the five pillars in the Buffett-Fit score on this page. ONC and RPRX are each scored on ROIC sustainability, gross-margin durability, and qualitative signals like brand strength, switching costs, network effects, and regulatory barriers. The pillar breakdown on this page shows the moat sub-score side-by-side so you can see which one has the more durable competitive advantage.

Which is more undervalued, ONC or RPRX?

Valuation is one of the five Buffett-Fit pillars on this page. Both stocks are scored on owner-earnings yield, price-to-intrinsic-value vs the underlying compounding rate, and the margin of safety relative to a conservative DCF. The valuation sub-score in the table below tells you which one currently trades at a more attractive price relative to its underlying business quality.

Are ONC and RPRX both Healthcare stocks?

Yes — both BeOne Medicines Ltd. (ONC) and Royalty Pharma plc (RPRX) operate in the Healthcare sector. That makes this a direct sector-peer comparison, which is the apples-to-apples way to use the Buffett-Fit framework: the score weighs each stock against its sector's specific quality and valuation benchmarks (sector-relative bonus), so the cross-stock comparison isn't distorted by inter-sector base-rate differences.

Is this ONC vs RPRX comparison investment advice?

No. This page is an educational pattern-match against documented public frameworks (Buffett, Graham, Fisher, Lynch, Greenblatt, Munger, Smith), not personalised investment advice. The scores reflect how closely each stock matches each framework's documented criteria — they are not buy/hold/sell recommendations. Always do your own research and consult a licensed financial adviser for personalised advice.

Stock comparison

BeOne Medicines

Royalty Pharma

Scored across Buffett, Graham, Lynch and Greenblatt - plus a side-by-side metric table covering valuation, quality, growth and balance sheet.

ONC

BeOne Medicines

Market cap

$33.15B

Sector

Healthcare

RPRX

Royalty Pharma

Market cap

$23.44B

Sector

Healthcare

Overall winner

BeOne Medicines ONC

Wins on the combined sum of fit scores across all four strategies. Per-strategy breakdown below.

Fit scores by strategy

Strategy	ONC	RPRX	Winner
Warren Buffett	62D	66C	RPRX
Benjamin Graham	75D	84A	RPRX
Philip Fisher	84C	65C	ONC
Peter Lynch	75B	60C	ONC
Joel Greenblatt	49D	40D	ONC
Charlie Munger	56D	68D	RPRX
Terry Smith	60D	58D	ONC

Side-by-side metrics

Metric	ONC	RPRX
Market cap	$33.15B	$23.44B
P/E (TTM)	107.5x	27.6x
EV/EBIT	28.9x	19.9x
ROIC (TTM)	7.73%	8.43%
Gross margin	87.17%	99.95%
Net margin	8.93%	33.91%
Revenue CAGR 5y	45.99%	0.96%
EPS CAGR 5y	67.36%	11.83%
Debt / Equity	0.4x	1.3x
Dividend yield	0.0%	1.72%

Where each one wins

The metrics with the biggest gap between the two - sorted so the most decisive edges read first.

ONC leads on

Revenue CAGR 5y45.99%vs 0.96%+98%
EPS CAGR 5y67.36%vs 11.83%+82%
Debt / Equity0.4xvs 1.3x+67%
Market cap$33.15Bvs $23.44B+29%

RPRX leads on

Dividend yield1.72%vs 0.0%+100%
P/E (TTM)27.6xvs 107.5x+74%
Net margin33.91%vs 8.93%+74%
EV/EBIT19.9xvs 28.9x+31%

More like ONC

ONC vs HALO ONC vs LMAT ONC vs RMD ONC vs LLY ONC vs UTHR ONC vs HAE

More like RPRX

RPRX vs HALO RPRX vs LMAT RPRX vs RMD RPRX vs LLY RPRX vs UTHR RPRX vs HAE

Read the full Buffett-Brain analysis for ONC Read the full Buffett-Brain analysis for RPRX

Related on invest-like

Strongest Moat Highest ROIC Warren Buffett strategy Economic Moat

Key terms in this analysis

ROIC Free Cash Flow (FCF)Economic Moat P/E Ratio Margin of Safety Quality Score

Educational tool. Fit scores are deterministic projections from public financials onto each investor's published criteria - not personal recommendations or advice.

Stock comparison

BeOne Medicines

Royalty Pharma

Scored across Buffett, Graham, Lynch and Greenblatt - plus a side-by-side metric table covering valuation, quality, growth and balance sheet.

ONC

BeOne Medicines

Market cap

$33.15B

Sector

Healthcare

RPRX

Royalty Pharma

Market cap

$23.44B

Sector

Healthcare

Overall winner

BeOne Medicines ONC

Wins on the combined sum of fit scores across all four strategies. Per-strategy breakdown below.

Fit scores by strategy

Strategy	ONC	RPRX	Winner
Warren Buffett	62D	66C	RPRX
Benjamin Graham	75D	84A	RPRX
Philip Fisher	84C	65C	ONC
Peter Lynch	75B	60C	ONC
Joel Greenblatt	49D	40D	ONC
Charlie Munger	56D	68D	RPRX
Terry Smith	60D	58D	ONC

Side-by-side metrics

Metric	ONC	RPRX
Market cap	$33.15B	$23.44B
P/E (TTM)	107.5x	27.6x
EV/EBIT	28.9x	19.9x
ROIC (TTM)	7.73%	8.43%
Gross margin	87.17%	99.95%
Net margin	8.93%	33.91%
Revenue CAGR 5y	45.99%	0.96%
EPS CAGR 5y	67.36%	11.83%
Debt / Equity	0.4x	1.3x
Dividend yield	0.0%	1.72%

Where each one wins

The metrics with the biggest gap between the two - sorted so the most decisive edges read first.

ONC leads on

Revenue CAGR 5y45.99%vs 0.96%+98%
EPS CAGR 5y67.36%vs 11.83%+82%
Debt / Equity0.4xvs 1.3x+67%
Market cap$33.15Bvs $23.44B+29%

RPRX leads on

Dividend yield1.72%vs 0.0%+100%
P/E (TTM)27.6xvs 107.5x+74%
Net margin33.91%vs 8.93%+74%
EV/EBIT19.9xvs 28.9x+31%

More like ONC

ONC vs HALO ONC vs LMAT ONC vs RMD ONC vs LLY ONC vs UTHR ONC vs HAE

More like RPRX

RPRX vs HALO RPRX vs LMAT RPRX vs RMD RPRX vs LLY RPRX vs UTHR RPRX vs HAE

Read the full Buffett-Brain analysis for ONC Read the full Buffett-Brain analysis for RPRX

Related on invest-like

Strongest Moat Highest ROIC Warren Buffett strategy Economic Moat

Key terms in this analysis

ROIC Free Cash Flow (FCF)Economic Moat P/E Ratio Margin of Safety Quality Score

Educational tool. Fit scores are deterministic projections from public financials onto each investor's published criteria - not personal recommendations or advice.